Age-related changes of cystatin C expression and polarized secretion by retinal pigment epithelium: Potential age-related macular degeneration links

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 2, 2014, Pages 926-934

  Kay, Paul ^a   Yang, Yit C ^b   Hiscott, Paul ^a   Gray, Donna ^a   Maminishkis, Arvydas ^c   Paraoan, Luminita ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^c NATIONAL EYE INSTITUTE   (United States)

Author keywords

Aging; Cystatin C; Retinal pigment epithelium; Secretion

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CYSTATIN C;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FETUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; WESTERN BLOTTING;

AGING; CYSTATIN C; RETINAL PIGMENT EPITHELIUM; SECRETION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; BLOTTING, WESTERN; BRUCH MEMBRANE; CELLS, CULTURED; CYSTATIN C; CYSTEINE PROTEINASE INHIBITORS; ELECTRIC IMPEDANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOHISTOCHEMISTRY; MACULAR DEGENERATION; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RETINAL PIGMENT EPITHELIUM; TISSUE DONORS; YOUNG ADULT;

EID: 84894083203     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13239     Document Type: Article

References (66)

1. Kay P, Yang YC, Paraoan L. Directional protein secretion by the retinal pigment epithelium: roles in retinal health and the development of age-related macular degeneration. J Cell Mol Med. 2013;17:833-843.
2. Kokkinopoulos I, Shahabi G, Colman A, Jeffery G. Mature peripheral RPE cells have an intrinsic capacity to proliferate: a potential regulatory mechanism for age-related cell loss. PLoS One. 2011;6:e18921.
3. Al-Hussaini H, Kam JH, Vugler A, Semo M, Jeffery G. Mature retinal pigment epithelium cells are retained in the cell cycle and proliferate in vivo. Mol Vis. 2008;14:1784-1791.
4. An E, Lu X, Flippin J, et al. Secreted proteome profiling in human RPE cell cultures derived from donors with age related macular degeneration and age matched healthy donors. J Proteome Res. 2006;5:2599-2610.
5. Paraoan L, Grierson I, Maden BE. Analysis of expressed sequence tags of retinal pigment epithelium: cystatin C is an abundant transcript. Int J Biochem Cell Biol. 2000;32:417-426.
6. Wistow G, Bernstein SL, Wyatt MK, et al. Expressed sequence tag analysis of human RPE/choroid for the NEIBank Project: over 6000 non-redundant transcripts, novel genes and splice variants. Mol Vis. 2002;8:205-220.
7. Ida H, Boylan SA, Weigel AL, et al. EST analysis of mouse retina and RPE/choroid cDNA libraries. Mol Vis. 2004;10:439-444.
8. NEIBank. NEIBank Website. Available at: http://neibank.nei. nih.gov/cgi-bin/libList.cgi?tissue=rpe. Accessed September 8, 2013.
9. Abrahamson M, Grubb A, Olafsson I, Lundwall A. Molecular cloning and sequence analysis of cDNA coding for the precursor of the human cysteine proteinase inhibitor cystatin C. FEBS Lett. 1987;216:229-233.
10. Paraoan L, White MR, Spiller DG, Grierson I, Maden BE. Precursor cystatin C in cultured retinal pigment epithelium cells: evidence for processing through the secretory pathway. Mol Membr Biol. 2001;18:229-236.
11. Zurdel J, Finckh U, Menzer G, Nitsch RM, Richard G. CST3 genotype associated with exudative age related macular degeneration. Br J Ophthalmol. 2002;86:214-219.
12. Hua Y, Zhao H, Lu X, Kong Y, Jin H. Meta-analysis of the cystatin C(CST3) gene G73A polymorphism and susceptibility to Alzheimer's disease. Int J Neurosci. 2012;122:431-438.
13. Kaur G, Levy E. Cystatin C in Alzheimer's disease. Front Mol Neurosci. 2012;5:79.
14. Paraoan L, Ratnayaka A, Spiller DG, Hiscott P, White MRH, Grierson I. Unexpected intracellular localization of the AMDassociated cystatin C variant. Traffic. 2004;5:884-895.
15. Ratnayaka A, Paraoan L, Spiller DG, et al. A dual Golgi-and mitochondria-localised Ala25Ser precursor cystatin C: an additional tool for characterising intracellular mis-localisation leading to increased AMD susceptibility. Exp Eye Res. 2007;84: 1135-1139.
16. Barrett AJ. The cystatins: a diverse superfamily of cysteine peptidase inhibitors. Biomed Biochim Acta. 1986;45:1363-1374.
17. Turk V, Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 1991;285:213-219.
18. Baynes JW. The role of AGEs in aging: causation or correlation. Exp Gerontol. 2001;36:1527-1537.
19. Monnier VM, Sell DR, Nagaraj RH, et al. Maillard reactionmediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes. 1992; 41:36-41.
20. Thornalley PJ. The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the concept. Biochem Soc Trans. 2003;31:1341-1342.
21. Beattie JR, Pawlak AM, Boulton ME, et al. Multiplex analysis of age-related protein and lipid modifications in human Bruch's membrane. FASEB J. 2010;24:4816-4824.
22. Glenn JV, Beattie JR, Barrett L, et al. Confocal Raman microscopy can quantify advanced glycation end product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging. FASEB J. 2007;21: 3542-3552.
23. Glenn JV, Mahaffy H, Wu K, et al. Advanced glycation end product (AGE) accumulation on Bruch's membrane: links to age-related RPE dysfunction. Invest Ophthalmol Vis Sci. 2009; 50:441-451.
24. Schutt F, Bergmann M, Holz FG, Kopitz J. Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2003;44:3663-3668.
25. Howes KA, Liu Y, Dunaief JL, et al. Receptor for advanced glycation end products and age-related macular degeneration. Invest Ophthalmol Vis Sci. 2004;45:3713-3720.
26. Handa JT, Verzijl N, Matsunaga H, et al. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. Invest Ophthalmol Vis Sci. 1999;40: 775-779.
27. Ishibashi T. Advanced glycation end products in age-related macular degeneration. Arch Ophthalmol. 1998;116:1629-1632.
28. Glenn JV, Mahaffy H, Dasari S, et al. Proteomic profiling of human retinal pigment epithelium exposed to an advanced glycation-modified substrate. Graefes Arch Clin Exp Ophthalmol. 2012;250:349-359.
29. Honda S, Farboud B, Hjelmeland LM, Handa JT. Induction of an aging mRNA retinal pigment epithelial cell phenotype by matrix-containing advanced glycation end products in vitro. Invest Ophthalmol Vis Sci. 2001;42:2419-2425.
30. Maminishkis A, Chen S, Jalickee S, et al. Confluent monolayers of cultured human fetal retinal pigment epithelium exhibit morphology and physiology of native tissue. Invest Ophthalmol Vis Sci. 2006;47:3612-3624.
31. Davies L, Gray D, Spiller D, et al. P53 apoptosis mediator PERP: localization, function and caspase activation in uveal melanoma. J Cell Mol Med. 2009;13:1995-2007.
32. Howard C, Garcia-Finana M, Yan Q, Hiscott P. Human retinal pigment epithelial SPARC expression and age: an immunohistochemical study. Histol Histopathol. 2010;25:1163-1169.
33. Sonoda S, Spee C, Barron E, Ryan SJ, Kannan R, Hinton DR. A protocol for the culture and differentiation of highly polarized human retinal pigment epithelial cells. Nat Protoc. 2009;4: 662-673.
34. Stitt AW, Hughes SJ, Canning P, et al. Substrates modified by advanced glycation end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet-derived growth factor. Diabetologia. 2004;47:1735-1746.
35. van Soest SS, de Wit GM, Essing AH, et al. Comparison of human retinal pigment epithelium gene expression in macula and periphery highlights potential topographic differences in Bruch's membrane. Mol Vis. 2007;13:1608-1617.
36. Benussi L, Ghidoni R, Steinhoff T, et al. Alzheimer diseaseassociated cystatin C variant undergoes impaired secretion. Neurobiol Dis. 2003;13:15-21.
37. Ghidoni R, Paterlini A, Albertini V, et al. Cystatin C is released in association with exosomes: a new tool of neuronal communication which is unbalanced in Alzheimer's disease. Neurobiol Aging. 2011;32:1435-1442.
38. Yamamoto-Watanabe Y, Watanabe M, Jackson M, et al. Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3. Brain Res. 2010;1361:140-145.
39. Zhong XM, Hou L, Luo XN, et al. Alterations of CSF cystatin C levels and their correlations with CSF Aβ40 and Aβ42 levels in patients with Alzheimer's disease, dementia with Lewy bodies and the atrophic form of general paresis. PLoS One. 2013;8: e55328.
40. Booij JC, Baas DC, Beisekeeva J, Gorgels TGMF, Bergen AAB. The dynamic nature of Bruch's membrane. Prog Retin Eye Res. 2010;29:1-18.
41. Karwatowski WS, Jeffries TE, Duance VC, Albon J, Bailey AJ, Easty DL. Preparation of Bruch's membrane and analysis of the age-related changes in the structural collagens. Br J Ophthalmol. 1995;79:944-952.
42. Starita C, Hussain A, Pagliarini S, Marshall J. Hydrodynamics of ageing Bruch's membrane: implications for macular disease. Exp Eye Res. 1996;62:565-572.
43. Hartnett ME, Lappas A, Darland D, McColm JR, Lovejoy S, D'Amore PA. Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epithelial barrier dysfunction via a soluble VEGF-dependent mechanism. Exp Eye Res. 2003;77:593-599.
44. Wittchen ES, Hartnett ME. The small GTPase Rap1 is a novel regulator of RPE cell barrier function. Invest Ophthalmol Vis Sci. 2011;52:7455-7463.
45. Ghiso J, Saball E, Leoni J, Rostagno A, Frangione B. Binding of cystatin C to C4: the importance of sense-antisense peptides in their interaction. Proc Natl Acad Sci U S A. 1990;87:1288-1291.
46. Sparrow JR, Ueda K, Zhou J. Complement dysregulation in AMD: RPE-Bruch's membrane-choroid. Mol Aspects Med. 2012; 33:436-445.
47. Abrahamson M, Olafsson I, Palsdottir A, et al. Structure and expression of the human cystatin C gene. Biochem J. 1990; 268:287-294.
48. Xu Y, Schnorrer P, Proietto A, et al. IL-10 controls cystatin C synthesis and blood concentration in response to inflammation through regulation of IFN regulatory factor 8 expression. J Immunol. 2011;186:3666-3673.
49. Bjarnadóttir M, Grubb A, Olafsson I. Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. Scand J Clin Lab Invest. 1995;55:617-623.
50. Solem M, Rawson C, Lindburg K, Barnes D. Transforming growth factor beta regulates cystatin C in serum-free mouse embryo (SFME) cells. Biochem Biophys Res Commun. 1990; 172:945-951.
51. El-Sukkari D, Wilson NS, Hakansson K, et al. The protease inhibitor Cystatin C is differentially expressed among dendritic cell populations, but does not control antigen presentation. J Immunol. 2003;171:5003-5011.
52. Ma W, Lee SE, Guo J, et al. RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Invest Ophthalmol Vis Sci. 2007; 48:1355-1361.
53. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21 ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem. 1997;272:17810-17814.
54. Bondeva T, Wojciech S, Wolf G. Advanced glycation end products inhibit adhesion ability of differentiated podocytes in a neuropilin-1-dependent manner. Am J Physiol Renal Physiol. 2011;301:F852-F870.
55. Hu P, Lai D, Lu P, Gao J, He H. ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells. Int J Mol Med. 2012;29:613-618.
56. Liu Y, Liang C, Liu X, et al. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-κB pathways. Atherosclerosis. 2010;208:34-42.
57. Yim MB, Yim HS, Lee C, Kang SO, Chock PB. Protein glycation: creation of catalytic sites for free radical generation. Ann N Y Acad Sci. 2001;928:48-53.
58. II in neonatal mesangial cells. Am J Physiol Renal Physiol. 2000;278:F676-F683.
59. Min C, Kang E, Yu SH, Shinn SH, Kim YS. Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. Diabetes Res Clin Pract. 1999;46:197-202.
60. Sonoda S, Sreekumar PG, Kase S, et al. Attainment of polarity promotes growth factor secretion by retinal pigment epithelial cells: relevance to age-related macular degeneration. Aging (Albany NY). 2010;2:28-42.
61. Ablonczy Z, Dahrouj M, Tang PH, et al. Human retinal pigment epithelium cells as functional models for the RPE in vivo. Invest Ophthalmol Vis Sci. 2011;52:8614-8620.
62. Sugahara K, Kiyota T, Clark RA, Mason RJ. The effect of fibronectin on cytoskeleton structure and transepithelial resistance of alveolar type II cells in primary culture. Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64:115-122.
63. Sheikpranbabu S, Haribalaganesh R, Lee KJ, Gurunathan S. Pigment epithelium-derived factor inhibits advanced glycation end products-induced retinal vascular permeability. Biochimie. 2010;92:1040-1051.
64. Dahrouj M, Alsarraf O, Liu Y, Crosson CE, Ablonczy Z. C-type natriuretic peptide protects the retinal pigment epithelium against advanced glycation end product-induced barrier dysfunction. J Pharmacol Exp Ther. 2013;344:96-102.
65. Li W, Stramm LE, Aguirre GD, Rockey JH. Extracellular matrix production by cat retinal pigment epithelium in vitro: characterization of type IV collagen synthesis. Exp Eye Res. 1984;38:291-304.
66. Whitcomb EA, Shang F, Taylor A. Common cell biologic and biochemical changes in aging and age-related diseases of the eye: toward new therapeutic approaches to age-related ocular diseases. Invest Ophthalmol Vis Sci. 2013;54:ORSF31-ORSF36.